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Abstract
Neurodegenerative diseases, such as Parkinson’s disease (PD), afflict millions worldwide.
Of greater concern is the fact that a main risk factor this disease is aging and the baby boomer
population is now reaching a geriatric age. Despite the active research in this area, little progress
has been made in the development of therapeutic strategies and furthering of our understanding in
pinpointing the causal events that onset these disease processes. Our lab has focused on studying
the protein homeostasis of key biomarkers in neurodegenerative diseases and examining whether
natural compounds can act as neuro-protectants and, thus, attenuate the pathology that ensues in
these conditions. First, we sought to determine whether Na-β-hydroxybutyrate (NaβHB) could
serve as a prophylactic for PD. We did so by using an organismal, vertebrate model (rat) to induce
a Parkinsonian condition via chronic injection of rotenone, a known mitochondrial complex I
inhibitor. Animals underwent behavioral testing to ascertain the presence of motor deficits. After
the behavioral testing, tissue was collected to perform immunohistochemical analysis. The
potential of NaβHB to rescue neurons and protect from damage was determined by counting the
number of TH-positive neurons in the Substantia Nigra pars compacta (SNpc). The exact causal
agents of Parkinson’s disease and Alzheimer’s disease (AD) are unknown; however, there are
biochemical and cellular changes that are common to both, such as: oxidative stress, mitochondrial
dysfunction and protein aggregation. Given the commonalities of these two disease processes, we
aimed to examine whether we could intercede in the pathogenesis caused by the prion-like protein,
β-amyloid (AD associated), when introduced to a non-native environment and allowed to interact
with another prion-like protein, α-synuclein. The molecule of choice was Tanshinone IIA, a
polyphenol found in red sage, which has the potential to scavenge free radicals and has shown
promise in other areas of biomedical research.
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Chapter 1: Background and Introduction
1.1 Parkinson’s Disease
1.1.1 Disease Overview
Parkinson’s disease (PD) is the second most common neurodegenerative disorder; it afflicts
approximately half a million people in the United States, and about 50,000 people are newly
diagnosed every year.1 Males are about two times as likely as females to develop the disease. The
disease is characterized by both motor and non-motor symptoms, but most classically known for
the motor aspect. The most common motor symptoms include: tremors, rigidity/stiffness, slowness
of movement, and unsteady gait due to a loss of balance and coordination.2 However, some people
exhibit non-motor symptoms even prior to exhibiting motor symptoms, such as: apathy, excessive
daytime sleepiness, anhedonia, loss of smell and taste, constipation, insomnia, depression and
anxiety.3 Furthermore, many of these patients might go on to develop cognitive deficits as well,
this might be in part due to the overlap in pathologies, such as is seen in Lewy body dementia.
Hanagasi et al. found that approximately 33% of patients have mild cognitive impairments at the
moment of diagnosis and that about 50% of those that do not will go on to present cognitive deficits
two to six years from PD diagnosis.4 Thus, this disease is debilitating to the patient in the sense
that they are limited in their day to day activities and eventually might develop a co-morbidity (i.e.
PD with dementia).5 Not only is this a burden to the patient but to the family and caretakers as
well. Furthermore, there are few treatments/therapies for Parkinson’s disease despite the ongoing
research efforts, such as that of the Michael J. Fox Foundation. This highlights the importance of
furthering our knowledge of this disease process and in doing so, developing new and better
treatment options, if not a cure, and also, finding ways to prevent the disease from happening in
the first place.
1.1.2 Molecular Outcomes
1.1.2.1 Oxidative Stress

1

Oxidative stress seems to be a ubiquitous outcome or causative agent in many diseases,
ranging from: cancer to heart disease, and allergies to neurodegenerative diseases. 6-13 The human
body -living organisms in general- produces free radicals, such as reactive oxygen species (ROS),
as part of normal biological processes, namely cellular respiration. 3 Nevertheless, our bodies are
built with self-defense mechanisms such as glutathione, catalase and superoxide dismutase(SOD)
enzyme which can ‘neutralize’ these radicals. However, the problem arises when this balance is
perturbed, whether it be because of a genetic mutation in one of these enzymes (as is the case in
some patients with Amyotrophic Lateral Sclerosis with mutation in SOD gene) or because
environmental exposures are increasing these radical species in our organism. It is then that these
highly reactive species are able to attack lipids and cause lipid peroxidation or attack DNA or
proteins, causing subsequent damage. Oxidative stress is particularly of interest in
neurodegenerative diseases given that the brain is a high energy organ (undergoing high levels of
cellular respiration) and that there are many compounds (e.g. dopamine) that can be readily
oxidized to toxic species.7 Furthermore, the Substantia Nigra pars compacta (SNpc) -the brain
region mainly affected in PD- is rich in iron, thus rendering it more susceptible to oxidative damage
as iron can undergo Haber-Weiss and Fenton reactions to produce radicals.13 The study of
oxidative stress as a mechanism in PD was potentiated by the finding of the effects of the
metabolite of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). This compound was
ingested unknowingly by consumers of an illicit drug (MPPP) and they shortly after showed
strikingly similar symptoms to PD; it was later found that the metabolite of MPTP, 1-methyl-4phenylpyridinium (MPP+), is an inhibitor of complex I of the ETC (electron transport chain).14
1.1.2.2 Mitochondrial dysregulation
Given the pivotal role that the mitochondria has in cellular respiration, it is no surprise that
mitochondrial dysfunction has been found to be a hallmark of neurodegenerative disorders, namely
PD.9, 22-23 The importance of the mitochondria in neurodegenerative diseases has been highlighted
by the many models used for PD, such as rotenone and MPTP whose toxic effects derive from
their ability to inhibit complex I of the electron transport chain. Mitochondrial dysfunction is
2

dangerous for many reasons: 1) a ‘faulty’ mitochondria decreases the amount of energy being
produced, 2) calcium (an important secondary messenger) homeostasis is disrupted, and 3) can an
apoptotic cascade can be inititated.9 Familial versions of the disease have led to the discovery of
important proteins involved in the disruption of mitochondrial homeostasis. 23 Thus, dysfunctional
mitochondria are a hallmark of PD and therapeutically targeting this or preventing it is of clinical
interest.
1.1.2.3 Protein aggregation and α-synuclein
Parkinson’s disease is characteristically defined histologically by the presence of Lewy
body inclusions predominantly in the Substantia Nigra pars compacta. 15-20 These intracellular
inclusions are made up of misfolded, aggregated proteinaceous material, including: ubiquitinated
debris, synphilin-1, tubulin, SOD2 (superoxide dismutase 2), and many other components, but the
major component is α-synuclein.21 Given its large presence in Lewy bodies and some genetic
variations of the disease are due to SNCA( alpha-synuclein gene) mutations, there has been
extensive research on α-synuclein. Its function is still unclear but it appears to play a role in
synaptic trafficking and possibly other neuronal functions. Recently, given its presence in other
diseases as well (e.g. Lewy body dementia, Multiple System Atrophy), it has been proposed that
perhaps α-synuclein has the potential to act as a prion-like protein and, upon being misfolded, may
recruit other proteins to misfold as well. This theory has been supported by the fact that many
researchers have found that Lewy bodies or α-synuclein oligomers, after transplanting these into
the brain, can cause a PD like pathology in cellular models (i.e. SH-SY5Y neuroblastoma cell line)
and multiple organismal models (e.g. non-human primates, mice –transgenic and non-transgenicand rats).16-17, 19-20
1.1.3 Etiology/PD models
Given that the underlying etiology of idiopathic or sporadic PD is unknown, different
models have been developed to study the disease (in addition to genetic models to study the genetic
aspects of the disease); however, they are all imperfect and thus the model is chosen based on the
mechanisms one wishes to study. The most common cellular and organismal models, specifically
3

for the study of toxin based or impact of environmental factors in PD, are: 6-hydroxydopamine (6OHDA), rotenone, MPTP, paraquat, and alpha-synuclein/Lewy body infusion.24-29 Some of these
models are best to study behavioral outcomes, such as the unilateral 6-OHDA model which allows
you to compare the effects of an unaffected versus an affected hemisphere. However, this model
does not reproduce the classical Lewy body inclusions. 27 The MPTP model is very effective at
producing nigrostriatal lesions, however its efficacy as a behavioral model is not as robust in rat
models as it is in nonhuman primates.26,28 Furthermore, it does not show alpha-synuclein
aggregation. The rotenone model has been reported to show motor impairments as well as alphasynuclein aggregation; however, there is a high mortality rate. 25 The paraquat model shows
decreased tyrosine hydroxylase (TH) levels in the striatum but does not cause motor deficits nor
does it produce alpha-synuclein aggregation.29 These models have been used largely in part due to
the fact that they allow researchers to study the environmental toxin theory for sporadic PD. People
could be exposed to MPTP, or a similar analog, via recreational illicit drug use (very unlikely),
and rotenone and paraquat have been used as a pesticide and herbicide, respectively. However,
there is limited information in the literature about people who were exposed to these toxins
environmentally and later on developed the disease. Nevertheless, given the molecular and/or
behavioral outcomes associated with these toxins, they are useful models for the development of
prophylactics and therapeutics for sporadic PD.
1.2 Antioxidants –Nature as Nurture
Hippocrates said “Let your food be your medicine and your medicine be your food”.
Presently, many current pharmacological therapies have their origins in naturally derived
compounds. Ranging from digitoxin - a chemical originally found in the foxglove plant- which is
used to treat heart problems, to penicillin – produced by a fungus- to treat infections, time and time
again in history, we have found answers to medicinal ailments in nature. 6,30 Many naturally derived
compounds have been acclaimed for their antioxidant capabilities and many areas of nature await
to be tapped into to unearth their potential.

4

Chapter 2: Tanshinone IIA – Antioxidant or Fibril mitigator
2.1 Introduction
Tanshinone IIA, 1,6,6-trimethyl-8,9-dihydro-7H-napthol[1,2-g]benzofuran-10,11-dione,
belongs to the group of chemicals Tanshinones found in Chinese sage (Salvia miltiorrhiza), of
those it is the most abundant.31-35 This diterpene quinone , commonly referred to as Dan Shen
ketone, has been used in traditional Chinese medicine to treat cardiovascular diseases. However,
given that it has been reported to have antioxidant properties, it has gained popularity in other areas
of research where oxidative stress is a key player in disease onset and/or progression. Furthermore,
studies by Wang, et al. (2013) showed that Tanshinone IIA could directly interact with full length

Image 1: To the left is an image of the Chinese sage roots from which the lipophilic
Tanshinone IIA (structure shown on the right) is extracted.
peptide sequence of beta-amyloid (Aβ1-42) and prevent the formation of fibrils and, of greater
scientific interest, disassemble pre-formed fibrils. Thus, Tanshinone IIA is a perfect candidate to
use as a molecule capable of intersecting the prion-like trajectory that can be initiated by the betaamyloid peptide.36

2.2 Specific Aims
Specific Aim 1: To evaluate Tanshinone IIA as a potential neuroprotectant by first
determining the concentration at which it is not toxic to the neuroblastoma cell line, SH-SY5Y
5

Specific Aim 2: Evaluate if Tanshinone IIA can intervene in a heterotypic Parkinsonian
model and rescue SH-SY5Y from Aβ25-35 insult
2.3 Methodology
2.3.1 Chemical reagents and Biological agents
SH-SY5Y cell line was purchased from ATCC [ATCC CRL-2266]. SH-SY5Y cells were
transfected with pCMV6-SNCA plasmid made by a previous member of the lab. 1 Beta-amyloid
(25-35) [H-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH] peptide was purchased from
Anaspec. Tanshinone IIA (TIIA) was purchased from Selleckchem [S2365], and sodium-βhydroxybutyrate (NaβH) and rotenone (RT) were purchased from Sigma-Aldrich [T4952 and
54965]. Hoechst 33342, Propidium iodide (PI), and H2DCFDA were purchased from Life
Technologies [H1399, P1304MP, and D399, respectively].
Cell Culture: SH-SY5Y cells were cultured in Dulbecco’s Modified Eagle’s Medium/ F-12
formulation (DMEM/F-12) supplemented with 10% fetal bovine serum and 100 units
penicillin/100 µg of streptomycin antibiotic as a prophylactic. Cells were grown in an incubator
set at 37°C and 5% carbon dioxide. Cell line utilized was stably transfected to express α-synuclein
by previous lab members.36 Cells were detached with Gibco Trypsin-EDTA (0.25%) [25200072]
Amyloid-Beta preparation: The following preparation was followed for all experiments involving
the use of the amyloid-beta (25-35) peptide. The Aβ25-35 peptide was purchased as a lyophilized
powder from Anaspec (AS-24228). The powder was stored at -20°C in original container until
preparation. Prior to use, powder was allowed to equilibrate to room temperature, the entire
contents of the glass vial were then used to prepare a 5 mM stock solution in ultra-pure (milliQ)
water. The solution was then either used immediately for experiments or stored at -20°C for future
use.

2.3.2 Dose determination (Cytotoxicity Assay)
In order to use Tanshinone IIA as a mitigator of beta-amyloid induced damage, we needed
to determine an optimal concentration at which Tanshinone IIA would not be toxic to the SH6

SY5Y cells. A 96-well plate was seeded with 20,000 cells/well. A stock concentration of 5 mM
Tanshinone IIA was prepared in fresh DMSO once the cells were confluent. Serial dilutions were
made so as to add a range of concentrations (500 nM, 1 µM, 2.5 µM, 5 µM, 7.5 µM, 10 µM, 12.5
µM, 25 µM, 50 µM) to the cells with DMSO at no greater than 1% (v/v) in the culture medium. A
negative control of cells with media only was used and a solution of 100 µM hydrogen peroxide
was used as a positive control for cell death. This experiment was conducted both for a 24 h period
and a 48 h period. An hour before the conclusion of the 24 h and 48 h incubation period, Hoechst
33342 and Propidium Iodide were added to the cells at a final concentration of 1µg/ml. After an
hour incubation of these dyes, the plate was read in an InCell 2000Analyzer Bioimaging system
(GE Healthcare). Eight replicates were performed for each test, means are shown and +/- S.D. bars
are shown.
2.3.3 Oxidative Stress
A 96 well plate with 20,000 cells/well was seeded. Once plate reached confluency, SHSY5Y cell were then pretreated with Tanshinone IIA (2.5 μM and 7.5 μM) for 1 hour prior to the
addition of 20 μM Amyloid-beta peptide (prepared as described previously). A stock solution of
dichlorofluorescein diacetate-H2 was prepared in DMSO immediately prior to use. After 24 hour
incubation of treatments, the dye was added at a final concentration of 20 μM in phenol red free
media. Loading of the cells with the dye was allowed for 30 min under dark conditions at 37°C.
After this period, the relative intensities (A.U.) were then read in a microplate reader (Thermo
Fisher Fluoroskan Ascent) with filters set for an excitation of 485 nm and emission of 527 nm.
Images of fluorescence were captured with LSM 700 Zeiss confocal microscope using 5x
objective. Quadruplicate replicates for each treatment were performed, graphs show means with
+/- S.D. error bars.
2.3.4 Mitochondrial Dysregulation
Rhodamine 123 is a probe used to measure mitochondrial membrane potential. SH-SY5Y
cells were seeded at a confluency of 20,000 cells/well in a 96 well plate. Once cells were at 8090% confluency, they were treated with 2.5 μM and 7.5 μM for 1 hour prior to exposing them to
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20 μM Aβ25-35 for a 24 hour period. After the 24 h incubation, rhodamine 123 dissolved in DMSO
was added to the cells to a final concentration of 10 μM (1% v/v [DMSO/media]). The dye was
allowed to permeate the cells for 30 min in the dark at 37°C in phenol-free media. After the 30
min incubation, relative fluorescence intensities were read in a Fluoroskan Ascent microplate
reader with filters set at excitation of 485 nm and emission of 527 nm. Quadruplicate replicates
for each treatment were performed, graphs show means with +/- S.D. error bars.
2.3.5 Apoptosis Detection via Phosphatidylserine externalization
SH-SY5Y cells were seeded at 100,000 cells/ well in a 24-well tissue culture plate. Once
confluent, treatment of 2.5 μM and 7.5 μM TIIA was applied 1 hour prior to exposing the cells to
20 μM Aβ25-35. After 24 hour incubation, the culture media was transferred to flow tubes set on ice,
the remaining cells were detached using 0.25% EDTA-Trypsin and added to their respective flow
tube. The culture media cell mixture was then centrifuged at 1200 RPM for 5 min at 4°C on a table
top centrifuge. The supernatant was then discarded and cells were re-suspended in 100 μL of 1 X
binding buffer (BD Pharmingen) with Propidium Iodide (1 μg/mL) and Annexin V-FITC (BD
Pharmingen). The cells were then incubated in this mixture in the dark, on ice for 15 min. After
this incubation, an additional 400 μL of 1 X binding buffer was added to each flow tube. Samples
were then read on Gallios Flow Cytometer (Beckman Coulter). Parameters were set so that the
instrument would detect 10,000 events per sample, with a time limit of 3 minutes. Triplicates of
each treatment were performed, values shown are representative means with +/- S.D. bars shown.
2.4 Results and Discussion
2.4.1 Optimal Dose Determination
The toxicity of Tanshinone IIA (TIIA) at varying concentrations (500 nM-50 µM) was
determined using a differential nuclear stain method. Cells were incubated under standard
conditions with the compound for 24 and 48 hours; proper negative (media only) and positive
(hydrogen peroxide) controls for cell death were used. In order to determine the live/dead cell
ratio, Hoechst 33342 – a dye that readily permeates both live and dead cells- and Propidium Iodide
–a dye that can only permeate cells with an un-intact membrane- were used at a concentration of
8

1 µg/mL. Thus, Hoechst gave the count of total number of cells, whereas Propidium iodide positive
cells reflected the dead cells. As can be observed in Figure 1, after 24 hours, there was a dose
dependency to cell toxicity, but even at a concentration of 50 µM there were low percentages of

cell death (~8%) as compared to 100 µM hydrogen peroxide (~94%). However, the % of cell death
for 2.5 µM-50 µM TIIA was greater after a 48 hour incubation period. Given that all subsequent
experiments were carried out in 24 hour periods only, the 24 h results were used to determine the
optimal working concentrations. The concentration of 2.5 µM was the highest concentration that
still had approximately the same percentage of death as the vehicle alone (~1.6% for 2.5 µM,
~1.8% for DMSO alone) indicating that the compound itself is not toxic at this concentration; thus,
this concentration was used for consecutive experiments. Additionally, although 7.5 µM showed
a higher % of cell death (~4.6%), this concentration was used to establish proof of concept given
that this concentration has been reported to be therapeutic/bioactive by the literature.33-34
2.4.2 Programmed Cell Death
Apoptosis (Type I programmed cell death) has been well established as a mechanism that
takes place in the neurons affected in Parkinson’s disease. Consequently, many of the PD models
have been known to induce apoptosis –both in cell lines (e.g. PC12, SH-SY5Y) and in organismal
models (e.g. mice and rats). Protein aggregation, mitochondrial dysfunction and oxidative stress
9

(all events that occur in PD) can ultimately lead to apoptotic death. Thus, we set forth to determine
if Tanshinone IIA could protect the neuroblastoma cell line from amyloid-beta induced cell death.
However, as can be seen in Figure 2, there was no statistical significance in the difference of
apoptotic death in the Aβ treated cells as compared to the cells that were in standard culture
conditions with no treatment (p>0.05). Thus, rescuing potential of Tanshinone IIA could not be
measured, given that the insult itself did not cause apoptotic death. Nonetheless, it is noteworthy
to mention that despite the fact that the beta-amyloid peptide did not cause a statistically significant
change in cell death (apoptotic or necrotic) as can be seen in Image 2, there is a signature pattern
in the side scatter of cells that were treated with the amyloid beta peptide (note panel D, F and H
as compared to the others). Thus, although amyloid beta is not inducing phosphatidylserine

Image 2: Representative histograms of flow cytometric analysis of apoptosis. A)No treatment, B)Vehicle, C) 2.5
μM TIIA, D) 2.5 μM TIIA + 20 μM Aβ, E) 7.5 μM TIIA, F) 7.5 μM TIIA + 20 μM Aβ, G) 20 μM Aβ and H) 100
μM H2O2.
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Figure 2: Apoptosis Assay. Graph shows the averages of apoptotic and necrotic cells for all treatments.
Values shown are averages of independent triplicate measures with +/- S.D. error bars shown.

externalization to signal apoptosis, the cellular morphology is undergoing changes in response to
the presence of the peptide.37-38
2.4.3 Intracellular Reactive Oxygen Species
Increase in reactive oxygen species (ROS) and in turn, oxidative stress, is a hallmark of
PD. This intracellular cascade can be replicated in many disease models of PD, such as RT and
MPTP. Previous lab members of our group sought out to determine whether Aβ25-35 insult, would
induce an increase in reactive oxygen species.36 As Figure 3 shows, we were able to reproduce
their work and found that despite the toxic effect of Aβ25-35, it does not directly cause an increase
in the production of ROS, unlike hydrogen peroxide treatment which even at low concentrations
(100µM) produces statistically significant (p<0.05 as per a student’s t-test) higher amounts of ROS
than those found in cells with no insult.39-41
2.4.4 Mitochondrial Membrane Potential
Given that the mitochondria is the hearth of energy production in the cell, mitochondrial
integrity and homeostasis is vital to cell function and its disruption is a hallmark of many disease
processes, including PD. Oxidative stress and nitrosative stress are known to cause a cascade of
cellular events that ultimately result in decreased mitochondrial membrane potential (MMP). 42 As
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can be seen in Figure 4, the Beta-amyloid (25-35) peptide at a concentration of 20 µM caused a
decrease in mitochondrial membrane potential, just as the positive control hydrogen peroxide, as
compared to the cells that received no treatment. Furthermore, Tanshinone IIA was able to restore
the MMP when the cells were pre-treated with TIIA prior to amyloid-beta insult both at 2.5 µM
(p<0.01 [**]) and 7.5 µM (p<0.05 [*]). These results indicate that TIIA is capable of interfering
with the Aβ and attenuating its toxic effects to the cell.

Figure 3: ROS Assay: Bar graphs show averages for quadruplicate measures for each treatment. S.D. +/- shown.

Figure 4: MMP Assay: Averages for quadruplicate measures for each treatment. S.D. +/- shown.
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2.5 Conclusion
Collectively, we have used well-established and standard metrics to evaluate the ability of
a natural compound, Tanshinone IIA -which has been lauded for its antioxidant, anti-inflammatory
and lipase inhibitory activity- to rescue a neuroblastoma cell line in a heterotypic model where a
prion-like protein, Aβ, was used as a toxicant to reproduce hallmark cellular aberrations of a PD
model. Overall, Tanshinone IIA was non-toxic to the SH-SY5Y neuroblastoma cell line and
capable of protecting the cells from Aβ-induced mitochondrial dysregulation when the cells were
prophylactically treated with the compound. However, further assessments of Tanshinone IIA’s
therapeutic potential could not be made given that the Beta-amyloid peptide at a concentration of
20µM did not induce a marked increase in apoptosis or ROS production; which is contrary to the
case for most PD models. This suggests that the mechanism of toxicity of this prion-like protein is
distinct to that of current commonly used toxins used to model PD in a cell model (i.e. rotenone,
6-OHDA, MPTP). Thus, different experimental procedures to those used for such models should
be used to examine the effects of amyloid beta on a dopaminergic-like cell line. Previous literature
has shown that Tanshinone IIA might directly interact with specific residues in the full length
peptide sequence of Aβ1-42,34 this supports the idea that TIIA is not serving a role as a ROS
scavenger in this scenario but perhaps directly interacting with the peptide to prevent fibrillization
instead. Overall, none of the classical models of sporadic/idiopathic PD - toxin models such as
paraquat, rotenone, MPTP, or 6-OHDA- fully reproduce all of the cellular mechanisms associated
with the disease. This is corroborated by the fact that we have failed to develop new drugs or
therapies which can halt the disease progression, or cure it. Thus, new approaches need to be taken,
such as looking at the possible interaction of two distinct proteins, namely Aβ and α-synuclein,
namely) and how the two can together cause a mass exodus of protein misfolding. Then, with a
deeper understanding, we can test compounds which have demonstrated therapeutic potential and
to determine how they fare in a heterotypic landscape.
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Chapter 3: A ketone as a prophylactic for PD in a vertebrate model
3.1 Introduction
D-β-hydroxybutyrate is a ketone, mainly the byproduct of fatty acid oxidation in the liver
but it can also be made from ketogenic amino acids via first producing acetoacetate that is then
converted to D-β-hydroxybutyrate by the enzyme β-hydroxybutyrate dehydrogenase enzyme. This
ketone can be used by the brain as a
fuel source when there are low levels
of glucose. This small compound is
of interest given that it is produced
endogenously during states of fasting
and thus would intuit that it would
have little to no side effects if used as
a prophylactic agent. Furthermore,

Image 3: Diagram showing how D-beta-hydroxybutyrate can be
converted to acetoacetate which can then be converted to acetyl-CoA
and feed back into the TCA cycle.

Kabiraj, et al. (2016) showed in SH-SY5Y cell studies that NaβHB was able to rescue from
rotenone induced damage, and Tieu, et al. (2003) demonstrated that this specific stereoisomer, Dβ-hydroxybutyric acid, readily crosses the blood brain barrier (BBB) and rescued mice from MPTP
induced nigrostriatal damage when administered prophylactically via osmotic pumps at 1.6
mmol/kg/day in normal saline.43 Thus, D-β-hydroxybutyrate, shows promise as a prophylactic
agent that can protect from the pathology that ensues in toxin induced-PD models.
3.2 Specific Aims
Specific Aim 1: We proposed to evaluate whether the salt of D-β-hydroxybutyrate was
capable of preventing rotenone-induced motor deficits in a Lewis rat model via a battery of wellestablished behavioral tests.
Specific Aim 2: We proposed to examine the extent, if any, to which Sodium-βhydroxybutyrate was capable of protecting the dopaminergic neurons of the Substantia Nigra pars
compacta from rotenone-induced death.
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3.3 Methodology
3.3.1 Animals
Initially a pilot study was conducted with 21 male Lewis (LEW/Hla®CVF®) rats
purchased from Hilltop Lab Animals Inc. (Scottdale, Pennsylvania). For the expanded study, forty
male Lewis rats of 6 months of age, weighing approximately 400-600 g were purchased from
Envigo®. The holding room for the animals was on a reverse light cycle (lights off at 8:00 A.M.,
lights on at 8:00 P.M). The rats were pair-housed in IVC cages in a temperature controlled setting
(22+/-2°) and provided water and standard laboratory chow ad lib. All experiments with animals
were performed in accordance with the Institutional Animal Care and Use Committee of the
University of Texas at El Paso.
3.3.2 Materials:
Rotenone (RT), (+/-)-Sodium 3-hydroxybutyrate (NaβHB), and Sunflower seed oil from
Helianthus annus were all purchased from Sigma Aldrich (R8875-1G, 59465-10G-F and 889211L-F, respectively). Thionin acetate (229840250) was purchased from Acros Organics as a high
purity reagent. Ethanol (histological grade), xylene and dimethylsulfoxide (DMSO) were
purchased from Fisher Scientific (A405-20, X3S-4, and BP231-1, respectively).
3.3.3 Experimental Outline
In order to test the prophylactic/neuroprotective capability of sodium-β-hydroxybutyrate
in a rodent PD model, the following injection regimen was followed (as can be seen in Image 4).

Image 4: Scheme showing injection regimen.

Overall there were 5 groups: 1) no injection/control group, 2) vehicle (V), 3) sodium-βhydroxybutyrate, 4) sodium-β-hydroxybutyrate + rotenone, and 5) rotenone only. The no injection
group received no injection, these animals underwent the same handling practices, behavioral
testing and husbandry conditions as their rat mates but they were never injected or administered
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any treatment. The vehicle group received an injection corresponding to the same volume that the
rotenone rats would receive to serve as a control for the emulsion in which the rotenone was
prepared, which was made of 2%(v/v) DMSO in Mygliol medium chain triglycerides (gifted from
OLEO Chemicals) for the pilot study and 2% (v/v) DMSO in Sunflower seed oil for the expanded
study. The NaβHB administered to those in the NaβHB only group and those in the NaβHB and
rotenone group was prepared at a concentration of 50 mg/mL in normal saline (0.9% [w/v] sodium
chloride in ultra-pure, sterile water) and was administered at a dose of 200 mg/kg. The rotenone
powder was prepared as a 30 mg/mL stock solution in DMSO and then diluted Sunflower Seed
Oil to a 3 mg/mL solution; this solution was prepared fresh every 3-4 days, stored in the dark, and
re-suspended thoroughly prior to ensure a homogenous solution.25
3.3.4 Behavioral Testing
A total of four behavioral tests were performed to gauge the degree of motor deficits, if
any. All the behavioral tests mentioned below have been used by other neurodegeneration research
laboratories as a measure for PD model to determine presence/absence of motor deficits and
severity. The tests performed were as follows: 1) Adhesive removal test, 2) Forelimb Placement
test, 3) Cylinder test and 4) Akinesia Test.44
3.3.4.1 Adhesive Removal Test
This behavioral test, also known as the “sticky dot test” is meant to measure the somatomotor capabilities of the rat, to include: 1) somato-sensation and 2) motor. Avery® circular
adhesive sticky dots (12 mm diameter, red glow color) were placed bilaterally on the glabrous pad
of the forelimb paws. After the sticky dots have been secured on both the right and left forepaws,
the animal was then set inside of a clean cage and the timer was started, experimenters then
recorded time to contact (the amount of time it took for the animal to note that it had a foreign
stimulus and touch it to its mouth) and the time to removal (the total amount of time from when
the rat was placed down until when it removed the sticky dot from its paw. If the animal had not
yet touched or removed the sticky dot after three minutes, a time of 180 seconds was marked as
the final score for that measure. The time to contact is a measure of the animal’s sensory capability,
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whereas the time to removal is a reflection of its motor abilities. This test was conducted three
times and averaged. All data shown are averages and error bars reflect +/- S.D.
3.3.4.2 Forelimb Placement Test
A variety of the forelimb placement test was used that is meant to measure the rat’s
reflexes. For this experiment, the rat was placed on the edge of a tabletop so that all its limbs were
on a solid surface, then, one of its forelimbs was slid off of the tabletop so that it did not have a
solid support. The amount of time it took for the rat to place its forelimb back on the tabletop was
measured. This was done a total of three times for each forelimb. Values shown in Figure … are
averages and error bars represent +/- S.D.
3.3.4.3 Cylinder Test
This test is meant to measure the animal’s rearing behavior by exploiting its natural
exploratory tendencies. The rat will be placed in a Plexiglas cylinder of dimensions 30 cm (height)
x 20 cm (diameter). The test was conducted during the animal’s awake cycle in the dark and then
video recorded for 2 min. The number of rears (defined as when the animal is supporting itself
only on its two hind limbs and using its forelimbs to touch the walls of the cylinder) was then
calculated by two experimenters blinded to the treatment whom watched the videos and recorded
all paw touches within a 120 second time span. The test was just conducted once per animal given
that the very nature of this experiment relies on its novelty to the animal. The values of both
experimenters had to be at a minimum of a 95% concordancy. The values shown in Figure 11
reflect the averages and +/- S.D. error bars are shown.
3.3.4.4 Akinesia Test
For this experiment, a rat was placed in a Plexiglas chamber shaped as a triangle with
dimensions as follows: 15 cm (length) x 11 cm (width) x 13 cm (height), where the base side of
the triangle was open ended. In this experiment, the rat was placed so that its nose was touching
the inside of the apex. The experimenter then recorded the amount of time it took the animal to
exit the enclosure, start time was recorded when the rat was touching apex of the triangle and after
it was released, and end time was recorded when the nose of the animal passed the boundary line
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of the triangle (i.e. open ended side at the base of the triangle). The animal was allowed two
minutes to exit the enclosure, if they had not exited after the time allotted, a time of 120 seconds
was recorded and animal was removed from enclosure. This test was performed a total of three
times for each animal and values shown are averages with error bars shown being +/- S.D.
3.3.5 Neurochemistry
3.3.5.1 Monoamine assay
For pilot study, after the conclusion of behavioral testing animals were sacrificed for tissue
collection. The striatum (Caudate nucleus and Nucleus accumbens) were excised from the tissue
while the brain was on ice and then rapidly weighed. Immediately afterwards, tissue was placed in
a microcentrifuge tube in the internal standard solution [8 μM EDTA (ethylenediamine tetraacetic
acid), 400 μM sodium metabisulfite (Na2S2O5) in 0.05 N Perchloric acid with DHBA
(dihydroxybenzylamine) at 0.1 ng/μL] followed by sonication. The tissue was then centrifuged for
30 minutes at 10,000 x g at 4°C. Tissue was then filtered and placed in HPLC tubes and analytes
were processed within two weeks of isolation. Samples were ran on an ESA 542 autosampler
HPLC using an isochratic system with a C18 column coupled with an electrochemical detector. The
mobile phase was as follows: 69 mM sodium monobasic phosphate, 33 mM citric acid, 0.127 mM
EDTA, and 1.72 mM sodium octyl sulfate in 6% (v/v) methanol in water, pH 2.5. Analytes
detected were: dopamine, DHBA, 5-hydroxyindoleacetic acid, 5-hydroxytyramine, homovanillic
acid, 3, 4-dihydroxyphenylacetic acid (DOPAC), and norepinephrine (chromatogram not shown).
Figure 7 shows results for dopamine only as ng of dopamine present per mg of tissue analyzed.
3.3.5.2 Nissl Staining
In order to identify the region of interest, a representative section (one tissue section from
each of the five per well) was taken for Nissl staining. Nissl staining is a process which is based
on the use of a basic dye, such as Thionin acetate or Cresyl violet, to stain the negatively charged
nucleic acids (i.e. DNA and RNA). This staining method derives its name from the fact that Nissl
was a term used to refer to the endoplasmic reticulum (ER), and given the high abundance of
ribosomal RNA in the rough ER this region is heavily stained. Thus, with this method, nuclei and
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rough ER create characteristic patterns (as has been documented in atlases such as the Swanson
Atlas) in histological preparations which allow for the identification of different structures. 45
(Swanson) Brain tissue sections were removed from the cryo-protectant and washed in 1 X
Phosphate Buffered Saline then mounted onto previously subbed slides. The slides were then left
to dry overnight. The following day the sections underwent the following process for staining:
dehydration -using solutions of increasing ratio of ethanol/water (100% water to 100% ethanol)-,
then de-fattening – left in Xylene for 30 min-, then rehydrated, then placed in 0.25% Thionin
acetate in a solution of pH 4.5 for 30 seconds, and finally, sections were dehydrated as before and
after the xylene, tissue sections were allowed to dry and then cover slipped and sealed with
CytoSeal60 (Thermo Scientific; Catalog# 8310-16). Images were taken using BZ-X700 Keyence
All-In-One Fluorescence microscope with 2x objective, mosaic of images were made using the
instrument’s software.
3.3.5.3 Immunohistochemical detection of TH-positive neurons
For the longitudinal study, in order to determine the extent of the nigrostriatal lesion, if
any, the brain tissue of the rats was analyzed by immunohistochemistry. The rats were perfused
with approximately 500 mL of normal saline (0.9% sodium chloride in water) followed by
approximately 250-350 mL of 4% (w/v) paraformaldehyde (PFA) in 1X phosphate buffered saline
(PBS). The rat brain was then extracted and stored in 4% PFA in 1 X PBS overnight at 4° C. The
following day, brains were transferred to a 30% sucrose (w/v) in 1 X PBS solution for 48-72 hours.
The brains were then placed on a pedestal and covered in OTC (optimal temperature cutting
solution) and placed in a -20°C Leica CM1850 Cryostat for 30 – 120 min to allow complete
freezing of the brain prior to slicing. Once frozen, the brain was cut in coronal sections in 30 μm
thick sections. Brain sections were collected in a serial fashion, where 5 consecutive sections were
placed into the same well so that that singular well could account for the same atlas level. The
sections were stored in a cryoprotectant solution [30% (v/v) ethylene glycol/20% (v/v) glycerol in
1 X PBS] and stored at -20°C for later use. Sections were then immunolabeled for detection of TH
(tyrosine hydroxylase) positive neurons. The tissues were first washed in 1 X PBS, each section
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was washed three times for 8 minutes/wash. After washing off the cryoprotectant solution, tissues
were then blocked in blocking solution [2% normal goat serum (NGS) in 1 X PBS + 0.1% (v/v)
Triton X-100], to prevent non-specific interactions and for tissue permeabilization, for 2 h on a
shaker at room temperature. Afterwards, tissues were washed three times in 1 X PBS, for 8
min/wash. The sections were then placed in the primary antibody solution [Anti-tyrosine
hydroxylase (Mouse) (1:100) in 1 X PBS; Santa Cruz Biotechnology, Catalog#: sc-25269]
overnight at 4°C for 24 hr. After the conclusion of the incubation in primary antibody, tissues were
washed in 1 X PBS for 8 min/wash, three times. Tissues were then placed in secondary antibody
solution [Anti-Mouse- Alexa 488 conjugated antibody (1:2000 in blocking solution); Thermo
Scientific, Catalog# A11001] for a 2 h incubation at room temperature in the dark. The tissue
sections were then washed three times in 1 X PBS for 8 min/wash. Finally, tissues were incubated
for 10 minutes in Hoechst 33342 (10 μg/mL) in 1 X PBS at room temperature on a shaker for a
nuclear counterstain. Washes were then performed as previously mentioned. After staining, tissue
sections were mounted onto microscope slides; once tissue sections were dried, tissues were coverslipped using 50% (v/v) glycerol in 0.1 M sodium bicarbonate solution and sealed with clear nail
polish. Slides were allowed to dry overnight and then stored in 4 °C until imaging. Slides were
imaged using LSM 700 Zeiss Confocal Microscope. Images were taken using 10 x objective and
the same parameters were used for all images: 1024x1024 pixels, laser power of 2.0, speed of 7,
averaging of 8 and at 1.0 airy unit. Number of TH-positive neurons were quantified using FIJI (Fiji
Is Just Image J) software with cell counter plugin. The tyrosine hydroxylase (TH) positive neurons
of the Substantia Nigra pars compacta were quantified, a representative section corresponding to
page 37 of Swanson atlas (as corroborated via Nissl staining-mentioned previously) was used for
all animals. Experimenter was blinded to treatment.
3.4 Results and Discussion
3.4.1 Pilot Study
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A

pilot

study

was

conducted to determine the
effectiveness

of

a

2.5

mg/kg/day dose of rotenone
over a span of three days. The
same groups as mentioned
above (No injection, vehicle,
NaβHB, NaβHB +RT, and RT
only) were utilized; given that
this was a pilot study only three
animals were used per group.

Figure 5: Percent Body Weight of the rats as compared to a baseline weight
prior rotenone exposure. These are averages (n=3) of each group. Day 4
represents the first day of RT exposure and Day 6 represents the last day of RT
administration. Day 12 was after rats were allowed to recover from injection
regimen for 6 days from final injection

The prophylactic compound was administered for 7 days prior to the exposure to rotenone and
then the prophylactic was administered in conjunction with rotenone for 3 more days for a total of
10 days of NaβHB I.P. (intraperitoneal) injections and 3 days of rotenone I.P. injections. As can
be seen in Figure 5, rats experienced a drop (>5%) in body weight but nowhere near experimental
endpoints. There were no unexpected mortalities in this study. Overall, the forelimb placement test
showed no differences (data not shown, average ~0.18 seconds for all groups) amongst groups
(statistical analysis not shown) as this test measures the reflex ability of the rat, which is not
necessarily affected by nigrostriatal lesion. For the adhesive removal test, two measures were
recorded, the time to contact (defined as the amount of time it took for the rat to notice a foreign
stimuli on its paw) and the time to removal (as data is shown here, the amount of time from when
rat noticed foreign stimuli-contact- to the time it removed the foreign stimuli). Figure 8 shows
both measures, with time to contact shown on the left panel and time for removal on the right
panel. As can be observed, there were no differences amongst the group for time to contact. Given
that this is a measurement of somatosensory affects, it shows that the animal’s ability to sense
(feel) stimuli was not affected. However, although there were no statistically significant
differences, for the time to removal there is a pattern indicating that the group of rats treated with
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only rotenone took longer to perform the task; indicating that there might have had a slight motor
deficit. The cylinder test data, as can be seen in Figure 6, However, no conclusions can be drawn
from this behavioral data given that there was not sufficient power in this study determine effect
and to render any of the data statistically significant. In addition to the behavioral tests, a
neurochemical analysis was performed of the brain tissue to measure the levels of catecholamines
and their metabolites. Overall, serotonin, 5-HIAA, DOPAC, HVA, norepinephrine and dopamine
were measured. Figure 7 shows the levels of dopamine (ng/mg) in striatal tissue, each bar graph
is the average per group (n=3). The data obtained from the pilot study was used to design a more
robust experimental design for the rotenone administration in the subsequent study.
3.4.1.1 Behavioral Data

Figure 8: Adhesive Removal Test: For the Adhesive removal test two measures were recorded: time to contact and
time for removal. Both graphs show the averages for the left and right paw independently. The graph on the left
shows the time to contact, the Graph on the right shows the amount of time it took to remove the sticky dot. Values
shown here are averages (n=3/group) with +/- S.D. error bars.
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3.4.1.1.1

Adhesive Removal Test

The adhesive removal test was performed in the same manner as it was for the pilot study.
Just as was the case in the pilot study, there were no statistically significant differences in the
amount of time it took the rats to notice that they had a foreign stimuli on their forepaws, indicating
that their somato-sensation remained unaffected by rotenone treatment. As for the amount of time
it took for the rats to remove the foreign stimuli (sticky dot) there was great variation within the
groups, as can be seen in Figure 9. However, an unpaired student’s t- test showed that there was a
statistically significant difference between the average time it took the rotenone rats to remove the
sticky dot as compared to the control group (p<0.05) indicating that the rotenone did have an effect
on the motor ability of the rat to remove the foreign stimuli. Furthermore, the rat’s pre-treated with
NaβHB seemed to have had a protectant effect from the rotenone as the amount of time they took
on average was less than that of the rotenone group (p<0.05). However, interestingly so, this was
only seen for the Right paw. As for the left paw, there were no statistically significant differences
between the aforementioned groups. This may be explained by the fact that the rotenone group did
not perform uniformly (heterogeneous population), there was great variation within the group.
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3.4.1.1.2

Forelimb Placement Test

Most rats performed uniformly for this task, except for the rotenone group. There was one
rat within this group that took longer to perform the task and thus the vast difference in the range

Forelimb Placement Test

0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00

Figure 10: Forelimb Placement Test: The amount of time it took the rat to reflexively place its forepaw
back on a solid surface after sliding it off to dangle in open space. The values shown here are averages
of three trials for the left and right paw combined. Error bars shown represent standard deviation (n=46).

for this task. Overall, when the groups were compared using statistical analyses (student’s t-test),
there were no statistically significant differences (p-value>0.05) between the groups, as can be
seen in Figure 9. These results were expected given that only animals with (>80%) large bilateral
lesions would be expected to show a delayed response given that this behavioral test has more of
a reflex component to it and does not greatly involve the basal ganglia system and thus, would be
unperturbed by a PD model.
3.4.1.1.3

Cylinder Test

The cylinder test is a behavioral test commonly used to assess motor behavior in rat models.
The advantages of this test are that it requires no training given that this test exploits the rat’s
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innate desire to explore novel
environments. This test requires
the animal to be able to stand on
its hind paws and touch the walls
of the cylindrical enclosure using
an open paw with all digits
touching

the

wall

known as rearing).
rotenone

was

(behavior
Given that

administered

systemically (via I.P. injection)
motor deficits, if any, were expected in both hemispheres; however, the effects might be more
pronounced on one side versus the other. Thus, for this test, the animals were recorded over a
period of two minutes, the videos were then watched take-by-take every one-hundredth of a second
on Windows Photos program. Experimenter recording total paw touches (Left and Right) was
blinded to the treatment group. Although, there seemed to be a trend of less activity (less paw
touches) in the rotenone treated group, as well as the NaβHB + RT group, there were no statistically
significant differences as per a student’s t-test
(p-value>0.05). As was the case for most
behavioral tests, there was a lot of variability in
task performance within the group.
3.4.1.1.4

Akinesia Test

The akinesia test was meant to measure the
latency period for an animal to exit an enclosed
space, in this case a triangular enclosure. The
Figure 12: Akinesia (Corner Escape) Test: For this test,
rats performed the task three times. These three trials were
averaged for each animal. Individual animal means are
shown here as individual data points. Whisker plots show
the standard error and mean for each group. (n=4-6)

animals don’t want to feel trapped so when
placed in this enclosure, given that they have
their full motor capabilities, they should readily
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exit the apparatus. However, if the animal has motor difficulties, they would take a longer period
of time to escape.
3.4.1.1.5

Immunohistochemical Data

In order to determine the extent of the nigrostriatal lesion, if any, tissue sections were
stained for tyrosine hydroxylase (the rate limiting enzyme in the synthesis of dopamine). Images
of the fluorescently labeled neurons were taken on a Zeiss 700 LSM confocal microscope. Number
of TH-positive neurons were quantified for a singular representative section using Image J
software. Representative Images can be seen in Image 3. The averages of TH-positive neurons per

Image 5: Nissl Staining: Nissl staining was carried out on all sections (1 of every 5) in order to compare the
staining pattern (as can be seen on the left) to the Swanson atlas (seen on the right) and determine the level and
brain regions present. All sections immuno-stained for TH (tyrosine hydroxylase) were sections found to be
comparable to level 38 of the Swanson atlas as per the representative Nissl section.

Figure 13: TH immunostaining: In order to quantify the amount of dopaminergic neurons in the SNpc,
representative sections (as determined via Nissl staining) were incubated with anti-tyrosine
hydroxylase (Mouse) and then with anti-mouse conjugate with Alexa488. Sections were imaged with
LSM 700 Zeiss confocal microscope.
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group are shown on Figure 13. As was the case for the behavioral tests, there was large variability
within groups in number of TH-positive neurons and overall, the averages for each group were
comparable to each other, showing no statistically significant differences as per a student’s t-test
(p-value>0.05).

3.4.2 Conclusion
Rotenone has been repeatedly used as a PD model, including Cannon, et al. publishing in
2009 declaring it “A highly reproducible rotenone model”. However, the literature is riddled with
many other publications citing different doses, different routes of exposure, and different lengths
of exposure in order to recreate a PD model. It has been our experience that this model is
shortcoming in the terms of being reproducible. We did not see any signs of a nigrostriatal lesion
and none of the four behavioral assays showed any motor deficits across the group. Furthermore,
if we do a singular per animal analysis, the effect varied greatly from rat to rat. There was one rat
within the rotenone group that showed cataleptic signs (thus the large standard deviation in the
rotenone group); however, immunostaining did not show statistically significant diminishment in
dopaminergic neurons in the SNpc but odd histological markings were present throughout the
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tissue. Additionally, many of the rats had white fibers/plaques in or atop of the liver. Bacterial
infections were ruled out by autopsy, but otherwise, the causative agent for these physiological
abnormalities could not be determined. In addition, there were four mortalities throughout the
study, two died immediately after injection and the other two from rotenone overdose. Although
one pitfall of our study was small number of animals per group (n=4-6), we would be reluctant to
perform the study again to evaluate the potential of prophylactic compounds given the vast
variability in effect of the toxin. Although the rotenone model seems to be the ideal one when
testing for attenuation of Lewy body formation or protective capability of compounds as
antioxidants, the lack of consistency in this model makes it affects the ability of the researcher to
properly evaluate the efficacy of this compounds and it would appear unwise to refer to it solely
as a PD model given the many other organ systems that are being affected.

28

References
1. NIH- Research Portfolio Online Reporting tools (RePORT) Parkinson’s disease.
<https://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=109>
2. NIH-National Institute on Aging. Parkinson’s disease. <https://www.nia.nih.gov/
health/parkinsons-disease>
3. Sveinbjornsdottir, S. (2016) The clinical symptoms of Parkinson’s disease. Journal of
Neruochemistry. 139:S1
4. Aarsland, D. (2016) Cognitive impairment in Parkinson’s disease and dementia with Lewy
bodies. Parkinsonism and Related Disorders. 22:S144-S148.
5. Hanagasi, H.A., Tufekcioglu, Z., Emre, M. (2017) Dementia in Parkinson’s disease.
Journal of the Neurological Sciences. 374:26-31
6. Lu, J.M., Lin, P.H., Yao, Q, Chen, C. (2010) Chemical and molecular mechanisms of
antioxidants: experimental approaches and model systems. Journal of Cellular and
Molecular Medicine. 14(4): 840-860.
7. Uttara, B., Singh, A.V., Zamboni, P., Mahajan R.T. (2009) Oxidative stress and
neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic
options. Current Neuropharmacology. 7(1): 65-74.
8. Nimse, S.B., Pal, D. (2015) Free radicals, natural antioxidants, and their reaction
mechanisms. RSC Advances. 5:27986.
9. Wang, X., Wang, W., La, L., Perry, G., Lee, H.G., Zhu, X. (2014) Oxidative stress and
mitochondrial dysfunction in Alzheimer’s disease. Biochim. Biophys. Acta. 1842(8): 12401247.

29

10. Hwang, O. (2013) Role of oxidative stress in Parkinson’s disease. Experimental
Neurobiology. 22(1):11-17.
11. Jenner, P. (2003) Oxidative stress in Parkinson’s disease. Annals of Neurology. 53(53):
S26-S38.
12. Jenner, P. and Olanow, C.W. (1996) Oxidative stress and the pathogenesis of Parkinson’s
disease. Neurology. 47:161S-170S.
13. Birben, E., Sahiner, U.M., Sackesen, C., Erzurum, S., Kalayci, O. (2012) Oxidative stress
and antioxidant defense. World Allergy Organization Journal. 5(1):9-19.
14. Sian, J. Youdim, M.B.H., Riederer, P., Gerlach, M. (1999) MPTP-induced Parkinsonian
syndrome. Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. 6th. ed.
15. Power, J.H.T., Barnes, O.L., Chegini, F. (2015) Lewy bodies and the mechanisms of
neuronal cell death in Parkinson’s disease and dementia with Lewy Bodies. Brain
Pathology. 27(1):3-12.
16. Recasens, A., Dehay, B. Bove, J., Carballo-Carbajal, I., Dovero, S., Perez-Villalba, A.,
Fernagut, P.O., Blesa, J., Parent, A., Perier, C., Farinas, I., Obeso, J.A., Bezard, E., Vila,
M. (2014) Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology
and neurodegeneration in mice and monkeys. Annals of Neurology. 75:351-362.
17. Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B., Olanow, C.W. (2008) Lewy bodylike pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nature
Medicine. 14(5): 504-506.
18. Swirski, M., Miners, J.S., de Silva, R., Lashley, T., Ling, H., Holton, J., Revesz, T., Love,
S. (2014) Evaluating the relationship between amyloid-β and α-synuclein phosphorylated

30

at Ser129 in dementia with Lewy bodies and Parkinson’s disease. Alzheimer’s Research &
Therapy. 6(77):1-17.
19. Volpicelli-Daley, L.A., Luk, K.C., Patel, T.P., Tanik, S.A., Riddle, D.M., Stieber, A.,
Meaney, D.F., Trojanowski, J.Q., Lee, V.MY. (2011) Exogenous α-synuclein fibrils induce
lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 72:57-51.
20. Li, J.Y., Englund, E. Holton, J.L., Soulet, D., Hagell, P., Lees, A.J., Lashley, T., Quinn,
N.P., Rechnrona, S., Bjorklund, A., Widner, H., Revesz, T., Lindvall, O., Brundin, P.
(2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest hostto-graft disease propagation. Nature Medicine. 14(5): 501-503.
21. Emmzadeh, F.N. (2016) Alpha-synuclein structure, functions, and interactions. Journal of
Research in Medical Sciences. 21:29.
22. Daiber, A. (2010) Redox signaling (cross-talk) from and to mitochondria involves
mitochondrial pores and reactive oxygen species. Biochimica et Biophysica Acta. 1797:
897-906.
23. Ryan, B.J., Hoek, S., Fon, E.A., Wade-Martins, R. (2015) Mitochondrial dysfunction and
mitophagy in Parkinson’s: from familial to sporadic disease.
24. Blesa, J. Phani, S., Jackson-Lewis, V., Przedborski, S. (2012) Classic and new animal
models of Parkinson’s disease. Journal of Biomedicine and Biotechnology. 2012:845618.
25. Cannon, J.R., Tapias, V.M., Na, H.M., Honick, A.S., Drolet, R.E., Greenamyre, J.T. (2009)
A highly reproducible rotenone model of Parkinson’s disease. Neurobiology of Diseases.
34(2):279-290.
26. Sindhu, K.M., Banerjee, R., Senthilkumar, K.S., Saravanan, K.S., Raju, C., Rao, J.M.,
Mohanakumar, K.P. (2006) Rats with unilateral median forebrain bundle, but not striatal

31

or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to
amphetamine and apomorphine. Pharmacology, Biochemistry and Behavior. 84:321-329.
27. Ding, Y.M., Jaumotte, J.D., Signore, A.P., Zigmond, M.J. (2004) Effects of 6hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine
neurons and the impact of glial cell line-derived neurotrophic factor. Journal of
Neurochemistry. 89:776-787.
28. Kopin, I.J. (1987) MPTP: An industrial chemical and contaminant of illicit narcotics
stimulates a new era in research on Parkinson’s disease. Environmental Health
Perspectives. 75:45-51.
29. Lohitnavy, M., Chitsakhon, A., Jomprasert, K., Lohhitnavy, O., Reisfeld, B. (2017)
Development of a physiologically based pharmacokinetic model of paraquat. Conf. Proc.
IEEE. Eng. Med. Biol. Soc. 2017:2732-2735.
30. Dias, D.A., Urban, S., Roessner, U. (2012) A historical overview of natural products in
drug Discovery. Metabolites. 2(2) 303-336.
31. ACS. Molecule of the Week Archive. May 26, 2014. <https://www.acs.org/content/acs
/en/molecule-of-the-week/archive/t/tanshinone-iia.html>
32. PubChem. U.S. National Library of Medicine-National Center for Biotechnology
Information. Tanshinone IIA. <https://pubchem.ncbi.nlm.nih.gov/compound/ Tanshinone
_IIA#section=Names-and-Identifiers>
33. Zhang, Y. Jiang, P., Ye, M., Kim, S.H., Jiang, C., Lu, J. (2010) Tanshinones: sources,
pharmacokinetics and anti-cancer activities. International Journal of Molecular Sciences.
13(10):13621-13666.

32

34. Wang, Q., Yu, X., Patal, K, Hu, R., Chuang, S., Zhang, G., Zheng, J. (2013) Tanshinones
inhibit amyloid aggregation by amyloid-β peptide, disaggregate amyloid fibrils, and protect
cultured cells. A.C.S. Chemical Neuroscience. 4(6):1004-1015.
35. Peng, T., Jiang, Y., Farhan, M., Lazarovici, L.C., Zheng, W. (2019) Anti-inflammatory
effects of traditional Chinese medicines on preclinical in vivo models of brain ischemiareperfusion injury: prospects for neuroprotective drug discovery and therapy. Front.
Pharmacol. 10: 204.
36. Kabiraj, P., Marin, J.E., Varela-Ramirez, A., Narayan, M. (2016) An 11-mer amyloid beta
peptide fragment provokes chemical mutations and parkinsonian biomarker aggregation in
dopaminergic cells: a novel road map for “transfected” Parkinson’s. ACS Chemical
Neuroscience. 7:1519-1530.
37. Venderova, K., Park, D.S. (2012) Programmed cell death in Parkinson’s disease. Cold
Spring Harbor Perspectives in Medicine. 2(8):a009365.
38. Agus, H.H., Sengoz, C.O., Yilmaz, S. (2018) Oxidative stress-mediated apoptotic cell
death induced by camphor in sod1-deficieint Schizosaccharomyces pombe. Toxicol. Res.
8(2):216-226.
39. Wang, W., Zheng, L.L., Wang, F., Hu, Z.L., Wu, W.N., Gu, J., Chen, J.G. (2011)
Tanshinone IIA attenuates neuronal damage and the impairment of long term potentiation
induced by hydrogen peroxide. Journal of Ethnopharmacology. 134(1):147-155.
40. Yao, D., Gu, Z., Nakamura, T., Shi, Z.Q., Ma, Y, Gaston, B., Palmer, L.A., Rockenstein,
E.M., Zhang, Z., Masliah, E., Uehara, T., Lipton, S.A. (2004) Nitrosative stress linked to
sporadic Parkinson’s disease: s-nitrosylation of parkin regulates its E3 ubiquitin ligase
activity. PNAS. 101(29):10810-10814.
33

41. Uehara, T., Nakamura, T., Yao, D., Shi, Z.Q., Gu, Z., Ma, Y., Masliah, E., Nomura, Y.,
Lipton, S.A. (2006) S-nitrosylated protein disulphide isomerase links protein misfolding to
neurodegeneration. Nature. 441:513-517.
42. Firdaus, F., Zafeer, M.F., Anis, E., Ahmad, F., Hossain, M.M., Ali, A. Afzal, M. (2019)
Evaluation of phyto-medicinal efficacy of theymoquinone against arsenic induced
mitochondrial dysfunction and cytotoxicity in SH-SY5Y cells. Phytomedicine. 54(15):224230.
43. Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D.C., Yan, S.D., Naini, A., Vila, M.,
Jakson-Lewis, V., Ramasamy, R., Przedborski, S. (2003) D-β-hydroxybutyrate rescues
mitochondrial respiration and mitigates features of Parkinson disease. Journal of Clinical
Investigation. 112(6) 892–901.
44. Wishaw, I.Q., Haun, F., Kolb, B. (1999) Analysis of behavior in laboratory rodents.
In:Windhorst U., Johansson H. (eds) Modern Techniques in Neuroscience Research.
Springer, Berlin, Heidelberg.
45. Swanson, L.W. (1992) Brain maps: structure of the rat brain, 1st edition.

34

Vita
Lois Mendez obtained her Cellular and Molecular Biochemistry Degree, B.S. from the
University of Texas at El Paso. During her undergraduate years, she was part of the Chemistry
Peer Leading group where she first had the opportunity to learn different pedagogical techniques
under the mentorship of Dr. Becvar and other Chemistry professors.
Lois then went on to pursue her Master’s degree in the Chemistry and Biochemistry
Department of UTEP where she worked in Dr. Mahesh Narayan’s Laboratory for
Neurodegenerative Diseases. Her work focused on using small molecules as prophylactics in
cellular and organismal models of Parkinson’s disease. Lois’ publications include: “The
Neuroprotective role of Ferrostatin-1 Under Rotenone-Induced Oxidative Stress in Dopaminergic
Neuroblastoma Cells” in the Protein Journal (2015). Her teaching experience continued as a
teaching assistant for the Biology I-Introduction to Biology Lab for one semester and Chemistry
II (1105) Laboratory for three semesters.
After completing her M.S. in Chemistry, she will go on to pursue her M.D. / M.B.A. at the
Texas Tech University Health Sciences Center at Lubbock.
Contact Information: <l.mendez3@hotmail.com>

35

